Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity
Please use the box in the top-right corner of the screen to login or register.
Release Date: January 30, 2023
Expiration Date: January 30, 2024
Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, two experts discuss direct oral anticoagulants (DOACs) in patients with VTE and obesity and review updated guidelines. They will discuss safety and appropriate dosing strategies for patients with a certain BMI, as well as the use of prophylaxis. The program will conclude with a discussion on the use of DOACs in patients after bariatric surgery.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with venous thromboembolism.
Upon completion of this educational activity, participants should be able to:
- Discuss the impact of obesity on VTE pathophysiology and DOAC absorption, distribution, metabolism, and excretion in obese individuals
- Recall guideline recommendations for DOACs in obese patients and their relevance in light of emerging data
- Utilize DOACs in obese patients safely and effectively, for the prevention and treatment of VTE
- Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity – Rachel P. Rosovsky, MD, MPH and Stephan Moll, MD
Instructions for Participation and Credit
This activity is eligible for credit through January 30, 2024. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Rachel P. Rosovsky, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director of Thrombosis Research
Division of Hematology
Massachusetts General Hospital
Dr. Rachel Rosovsky earned her medical degree from Harvard Medical School and a master's in public health from Harvard School of Public Health. She completed her residency at Brigham and Women's Hospital, and her fellowship in hematology and medical oncology at the combined Dana-Farber Cancer Institute-Massachusetts General Hospital program. She is Assistant Professor of Medicine at Harvard Medical School, and Director of Thrombosis Research, Division of Hematology, and Co-Chair of the Massachusetts General Hospital (MGH) Thrombosis Committee.
Dr. Rosovsky, a board-certified hematologist, provides clinical care full-time, supervises trainees, and conducts research in thrombosis and hemostasis. She is a founder and vice president of the Pulmonary Embolism Response Team (PERT) Consortium, is on the executive committee, and is creator/director of PERT multidisciplinary follow-up clinic at MGH. In addition, she is on the medical/scientific advisory board for the National Blood Clot Alliance (NBCA) and on the executive committee for Venous thromboEmbolism Network US (VENUS). She serves on the committee on Quality for the American Society of Hematology (ASH), and on the thrombosis working group for the International Consortium for Health Outcomes Measurement (ICHOM). Dr. Rosovsky was recently awarded 2021 Massachusetts General Hospital Public Voices Fellowship, as well as the 2021 Anne Klibanski Visiting Scholars Award. She has collaborated worldwide with researchers on risks, diagnosis, and treatment of venous thromboembolism (VTE ) and she has published more than 80 scholarly manuscripts in these areas and presented numerous research and clinical presentations at national and international scientific conferences. Since the COVID-19 pandemic, Dr. Rosovsky has been actively involved in investigating how COVID-19 and coagulopathy are affecting patients worldwide. Through lecturing, research, and written works, she has sought to improve care of patients with VTE and advance understanding and treatment of this medical condition for the past 20 years.
Stephan Moll, MD
Department of Medicine
Division of Hematology-Oncology
University of North Carolina
Chapel Hill, North Carolina
Dr. Stephan Moll received his medical degree from Freiburg University, Germany, and performed a pathology residency at the Institute of Pathology, University of Aachen, Germany. He completed an internship/residency in internal medicine and a hematology-oncology fellowship at Duke University Medical Center, North Carolina, and a one-year clinical coagulation fellowship at the University of North Carolina (UNC), Chapel Hill. Dr. Moll has been a faculty member at the University of North Carolina in the Department of Medicine and the Division of Hematology-Oncology since 1999, now at the rank of full professor.
His clinical interest is coagulation and classical hematology, with a particular focus on thrombosis and anticoagulation. Dr Moll’s research interests include clinical trials on new anticoagulants and better use of established anticoagulants. He takes a special interest in clinical-medical education of patients, the public, and healthcare professionals, and is a cofounder of the UNC Blood Clot Education Program Clot Connect. His three main professional goals for the next 5-10 years are 1) enhance the Clot Connect information program, 2) continue to build an “Athletes and Blood Clot Program,” 3) support trainees in their career development in the field of coagulation/hematology.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-23-002-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Rachel Rosovsky has relevant financial relationships related to advisory and consulting activities from Bristol-Myers Squibb Company, Dova Pharmaceuticals Inc., INARI Medical, and Janssen Pharmaceuticals, Inc. She has received research grant(s) from Bristol Myers Squibb and Janssen.
Dr. Stephan Moll has relevant financial relationships related to consulting from Bristol Myers Squibb Company and Diagnostica Stago, Inc.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Please use the box in the top-right corner of the screen to login or register.